Avandia Health Concerns Crosses the Pond

We previously wrote concerning increased heart attack and heart failure risks to those taking the prescription drug Avandia (Rosiglitazone). The drug, manufactured by GlaxoSmithKline (GSK), is prescribed to Type II (non-insulin dependent) diabetics. The FDA has taken under advisement the issue of whether or not to increase warnings and precautions of taking the drug or to completely remove the drug from the U.S. market.
A September 5, 2010 article by BBC Panorama disclosed that the drug was recommended for withdrawal in the UK two months ago by an expert panel of the UK Medicines and Healthcare products Regulatory Agency (MHRA), the UK’s equivalent of the FDA. In July, clinicians at the Commission on Human Medicines (CHM), the MHRA’s advisory body, recommended unanimously that Avandia be withdrawn from the UK. This recommendation was not made public. MHRA has sent letters to healthcare officials, suggesting they should “consider alternative treatments where appropriate.”
Avandia has been prescribed to tens of thousand of patients in the UK over the last ten years, earning GSK billions of pounds. The European Medicines Agency, in a Europe- wide review of Avandia, will announce later this month whether or restrict Avandia’s prescription or to withdraw it completely. Meanwhile, GSK said its research proved the drug was “safe and effective when it is prescribed appropriately,” and that “patient safety is our first priority.”
Actos, a competitor drug to Avandia, is being widely prescribed in the U.S., although some studies claim to show that Actos is no more safe for Type II diabetics than Avandia.
The drug choice facing prescribing physicians and patients at this time is a difficult one and appears to be little more than a roll of the dice.

We Want to Hear aBOUT yOUR cASE

Schedule a Free Consultation Today 
  • Please enter your first name.
  • Please enter your last name.
  • Please enter your phone number.
    This isn't a valid phone number.
  • Please enter your email address.
    This isn't a valid email address.
  • Please make a selection.
  • Please enter a message.